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rsalan Shirwany, MD, FACC,†‡
arl T. Weber, MD, FACC†
emphis, Tennessee
everal decades ago, the severity of heart failure was gauged
ccording to a depression in myocardial contractility, de-
ned as that biochemical property of cardiac muscle that
etermines the extent of shortening independent of its
nitial length and the load against which it shortens.
athematical models were used to derive indices of con-
ractility (1). These theoretical constructs included a con-
ractile element tethered to elastic elements that were
ituated both in series and in parallel to it. Cardiomyocytes,
ith their actin and myosin protein microfilaments, consti-
ute the myocardium’s contractile elements, whereas fibrillar
ollagen is the anatomic correlate of these elastic elements.
See page 89
Cardiomyocytes are interconnected to form a syncytium
f branching cardiac muscle fibers. Once depolarized, these
bers generate a force that is transmitted to the ventricle,
roportionally translating into a rise in chamber pressure
uring systole. When this intracavitary pressure exceeds that
n the great vessels, blood is propelled into the pulmonic and
ystemic circulations. The transmission of this systolic force
o the ventricle is facilitated by a collagenous scaffolding that
rovides for the support and alignment of cardiac muscle
bers. Composed predominantly of type I and III fibrillar
ollagens, this scaffolding is often simply referred to as the
xtracellular matrix (2); it also contributes to the size and
hape of the ventricle and imparts a certain resistance to
issue deformation during ventricular filling. The tensile
trength of type I collagen approximates that of steel.
herefore, it is not surprising that matrix is a major
eterminant of myocardial stiffness during diastole (3,4).
On the basis of its morphologic features, as seen by scanning
lectron and light microscopy, this contiguous collagenous
etwork has been anatomically subdivided into epi-, peri-, and
ndomysium: the epimysium is located on endocardial and
picardial surfaces of the myocardium, where it respectively
rovides substrate for endothelial and mesothelial cells; the
pimysium extends into the interstitial space to form a perimy-
ium that surrounds and groups muscle fibers while its strands
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.T
From the †Division of Cardiovascular Diseases, University of Tennessee Health
cience Center, and the ‡Veterans Affairs Medical Center, Memphis, Tennessee.onnect groups of muscle fibers to one another; and the
ndomysium, which arises from the perimysium to surround
ndividual muscle fibers and whose struts tether muscle fibers
ogether, to their nutrient microvasculature, and to cardio-
yocyte actin-myosin microfilaments via their cytoskeletal
roteins (5,6). The exteriorized portion of the heart’s collagen
atrix forms chordae tendineae and valve leaflets that insert
nto respective annuli of the mitral and tricuspid valves. An
fficient muscular pump is created by contractile elements
esiding within a fibrillar collagen matrix.
Collagen is a stable protein whose balanced turnover (syn-
hesis and degradation) by cardiac fibroblasts is normally slow
estimated to be 80 to 120 days) (7). This balance can be lost
nder pathologic conditions related, in part, to the appearance
f a more active fibrogenic phenotype termed the myofibro-
last because it contains alpha-smooth muscle actin microfila-
ents and is contractile. Myofibroblast collagen turnover is
egulated by factors (autocrine and paracrine) generated within
he myocardium and by hormones (endocrine) derived from
he circulation. For example, angiotensin II produced locally by
ctivated macrophages and myofibroblasts regulates their ex-
ression of transforming growth factor-beta1, a fibrogenic
ytokine which, in turn, upregulates the expression of type I
nd III fibrillar collagen genes (8).
In morphologic terms, the accumulation of collagen can
resent as a reactive fibrosis (e.g., an adverse accumulation of
erimysial collagen) or as a reparative fibrosis (i.e., scar tissue)
hat replaces cardiomyocytes lost to necrotic cell death to
reserve the structural integrity of myocardium (reviewed in
eber [2]). Apoptotic cell death, devoid of an inflammatory
ell response, is not accompanied by fibrosis. In biochemical
erms, fibrosis is expressed as an increase in myocardial hy-
roxyproline concentration, an amino acid specific to collagen.
epending upon its location and magnitude, collagen fiber
rosslinking, and relative abundance of type I and III collagens,
brosis can adversely increase myocardial stiffness, leading to
iastolic heart failure (DHF), or, as more recently coined, heart
ailure with preserved ejection fraction (EF) (reviewed in Zile
nd Brutsaert [9,10]). Diastolic heart failure is commonly seen
ith the concentric hypertrophy that accompanies arterial
ypertension. In the dilated (idiopathic) cardiomyopathic
eart, a degradation of fibrillar collagen can dominate. This
ccurs when the proteolytic activity of latent matrix metallo-
roteinases (e.g., MMP-1) is activated to overcome endoge-
ous tissue inhibitors (e.g., TIMP-1) (reviewed in Spinale
11]). A loss of fibrillar collagen leads to muscle fiber slippage,
thinning of myocardium, ventricular chamber dilation and
phericalization, and the appearance of systolic heart failure
SHF) with reduced EF.
Hypertensive heart disease (HHD), ischemic heart disease
ith previous myocardial infarction(s), and a dilated (idio-
athic) cardiomyopathy represent the three major etiologic
actors that account for heart failure in this country. The failing
eart in HHD may present as predominant DHF or SHF.
he clinical syndrome congestive heart failure, with its char-
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Editorial Comment July 4, 2006:97–8cteristic signs and symptoms, can accompany either DHF or
HF. Its origins are rooted in a salt-avid state mediated by
ffector hormones of the renin-angiotensin-aldosterone sys-
em. Left ventricular hypertrophy (LVH) is a distinguishing
eature of HHD; so too is fibrosis, which is found throughout
he LV free wall, interventricular septum, and right ventricle. It
s not the quantity, but rather the quality (structural remodel-
ng) of myocardium that contributes to compromised function
nd arrhythmogenicity in HHD. Fibrous tissue is morpholog-
cally viewed as a perivascular fibrosis involving the intramural
oronary arterial vasculature, an interstitial fibrosis (accumu-
ated perimysium), and microscopic scarring (12). Recent
tudies suggest the amount of fibrous tissue found in HHD
ith either DHF or SHF can be comparable, whereas the
eometric remodeling of the LV chamber and myocardium are
uite different (13). This calls into question the balance
etween MMPs and TIMPs.
In this issue of the Journal, the investigative team of Javier
íez (13) located at the Centre for Applied Medical Re-
earch at the University of Navarra in Pamplona, Spain,
ddress this question. They hypothesized that enhanced
MP-mediated collagen degradation contributes to LV dila-
ion and decline in EF seen with SHF in HHD. Toward this
nd, they used a multifaceted approach to address the presence
nd magnitude of MMP-1 and TIMP-1 in tissue obtained by
ransvenous endomyocardial biopsy and the presence of free
MP-1 and TIMP-1 in blood taken from the heart’s major
enous effluent, the coronary sinus, and an antecubital vein. In
rief, patients with HHD having a clinical diagnosis of heart
ailure were found to have cardiac fibrosis, but one whose
orphologic presentation differed between SHF and DHF.
erivascular fibrosis and scarring occupied a greater portion of
yocardium while interstitial (or perimysial) collagen fibers
ere reduced in SHF. These morphologic findings were
ccompanied by increased protein expression of MMP-1
elative to TIMP-1 in tissue and blood, suggesting that an
mbalance in the MMP-1/TIMP-1 ratio may underlie LV
ilation and reduced EF in SHF. This elegant study raises the
rospect that noninvasive, serologic markers of collagen turn-
ver could be used to elucidate abnormalities in the heart’s
xtracellular matrix that could account for ventricular remod-
ling and dysfunction, thus providing a pathophysiologic cor-
elate as a discriminator of DHF or SHF. Furthermore, such
arkers could prove useful in monitoring interventions in-
ended to reverse such remodeling.
Additional questions arise, as should be the case for such
provocative study. Does HHD evolve as concentric LVH
ith DHF and transition to SHF with LV dilation and
educed EF? This scenario has been demonstrated in an
xperimental model of salt-sensitive hypertension (14). Is
uch a transition reversible? What accounts for unbridled
MP activity? Is it an activation of latent MMPs and/or
ncreased expression of MMPs? Is it a deficiency of TIMPs?
s there a role for reactive oxygen intermediates in activating
atent MMPs, and if so, what accounts for the induction of
xidative stress (15)?In closing, iterations in the heart’s extracellular matrix can
ontribute importantly to a structural remodeling of myocar-
ium that leads to ventricular dysfunction during either dia-
tolic or systolic phases of the cardiac cycle. In HHD, an
ncrease in interstitial collagen is associated with DHF,
hereas a degradation of endo- and perimysial components of
he collagen scaffolding is accompanied by ventricular dilata-
ion and reduced EF, or SHF. A better understanding of the
ole played by matrix in the failing, hypertrophied heart in
HD will broaden our perspective of its pathophysiologic
xpressions. The noninvasive monitoring of collagen turnover
sing serologic markers related to its synthesis and degradation
ay offer new insights. Factors regulating collagen turnover
synthesis and degradation) in HHD need to be identified so
s to address appropriate management strategies.
eprint requests and correspondence: Dr. Karl T. Weber,
ivision of Cardiovascular Diseases, University of Tennessee
ealth Science Center, 920 Madison Avenue, Suite 300, Mem-
his, Tennessee 38163. E-mail: KTWeber@utmem.edu.
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